Literature DB >> 7099520

Granulomatous reaction to Choyce style intraocular lens.

M C Kincaid, W R Green, W J Iliff.   

Abstract

Despite the large number of intraocular lens implants performed since Ridley first devised the procedure, there have been few reports of postmortem examination in clinically successful cases. We report a patient who tolerated his Choyce Mark VIII style implant well, despite a three-month episode of mild nongranulomatous uveitis occurring two months postoperatively, until his death 17 months later. This is the sixth postmortem study of an anterior chamber IOL and the only one in which there was a conspicuous granulomatous reaction on the anterior iris surface, with large foreign body giant cells. Despite the presence of a foreign body, the previous eyes that have clinically tolerated implants well and have come to postmortem examination have shown remarkably little inflammation; none have shown this degree of granulomatous reaction previously.

Entities:  

Mesh:

Year:  1982        PMID: 7099520

Source DB:  PubMed          Journal:  Ophthalmic Surg        ISSN: 0022-023X


  6 in total

1.  The histopathology of intraocular lenses.

Authors:  J B Crawford
Journal:  Trans Am Ophthalmol Soc       Date:  1984

2.  Foreign body giant cells on intraocular lens implants.

Authors:  J R Wolter
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1982       Impact factor: 3.117

3.  Aphakia versus pseudophakia. A clinico-pathological study.

Authors:  A Hamburg
Journal:  Int Ophthalmol       Date:  1985-03       Impact factor: 2.031

4.  Cystoid macular edema associated with limbal melanoma.

Authors:  J R Wolter
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1983       Impact factor: 3.117

5.  Histopathological findings in necropsy eyes with intraocular lenses.

Authors:  M S McMahon; J S Weiss; K G Riedel; D M Albert
Journal:  Br J Ophthalmol       Date:  1985-06       Impact factor: 4.638

6.  Pseudophaco-anaphylactic endophthalmitis?

Authors:  J R Wolter
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1983       Impact factor: 3.117

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.